Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | cell-cycle-associated protein kinase CDK, putative | 0.0043 | 0.0234 | 0.5 |
Plasmodium vivax | protein kinase Crk2 | 0.0043 | 0.0234 | 0.5 |
Loa Loa (eye worm) | CMGC/CDK/CDC2 protein kinase | 0.0043 | 0.0234 | 0.0234 |
Leishmania major | cell division related protein kinase 2,cdc2-related kinase | 0.0043 | 0.0234 | 0.5 |
Leishmania major | cell division protein kinase 2,cdc2-related kinase | 0.0043 | 0.0234 | 0.5 |
Trypanosoma cruzi | cdc2-related kinase 3 | 0.0043 | 0.0234 | 0.5 |
Trypanosoma brucei | cdc2-related kinase 1 | 0.0043 | 0.0234 | 0.5 |
Trypanosoma cruzi | cdc2-related kinase 3 | 0.0043 | 0.0234 | 0.5 |
Echinococcus multilocularis | 3 phosphoinositide dependent protein kinase 1 | 0.0101 | 1 | 1 |
Loa Loa (eye worm) | CMGC/CDK/CDC2 protein kinase | 0.0043 | 0.0234 | 0.0234 |
Giardia lamblia | Kinase, CMGC CDK | 0.0043 | 0.0234 | 0.5 |
Trypanosoma cruzi | cdc2-related kinase 1 | 0.0043 | 0.0234 | 0.5 |
Trypanosoma cruzi | cdc2-related kinase 1 | 0.0043 | 0.0234 | 0.5 |
Entamoeba histolytica | protein kinase, putative | 0.0101 | 1 | 1 |
Loa Loa (eye worm) | AGC/PDK1 protein kinase | 0.0101 | 1 | 1 |
Trichomonas vaginalis | AGC family protein kinase | 0.0101 | 1 | 1 |
Trypanosoma brucei | cdc2-related kinase 3 | 0.0043 | 0.0234 | 0.5 |
Echinococcus granulosus | 3-phosphoinositide-dependent protein kinase 1 | 0.0101 | 1 | 1 |
Loa Loa (eye worm) | AGC/PDK1 protein kinase | 0.0101 | 1 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0101 | 1 | 1 |
Trichomonas vaginalis | AGC family protein kinase | 0.0101 | 1 | 1 |
Plasmodium falciparum | protein kinase 5 | 0.0043 | 0.0234 | 0.5 |
Loa Loa (eye worm) | CMGC/CDK/CDK5 protein kinase | 0.0043 | 0.0234 | 0.0234 |
Brugia malayi | Protein kinase domain containing protein | 0.0101 | 1 | 1 |
Trichomonas vaginalis | AGC family protein kinase | 0.0101 | 1 | 1 |
Giardia lamblia | Kinase, CMGC CDK | 0.0043 | 0.0234 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.